Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...

AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...

The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...

Vertex Pharmaceuticals (VRTX) Incorporated announced that the U.S. Food and Drug Administration has approved JOURNAVX, an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the ...

Journavx is a first-in-class non-opioid ... in annual sales by 2030 would be a step in the right direction for Vertex Pharmaceuticals but this wouldn't be a transformative contribution.

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval ... reach the brain," according to the FDA. It will use Journavx as its brand name. GET FOX BUSINESS ON THE ...

Vertex Pharmaceuticals (NASDAQ ... Last Thursday, the agency approved Vertex's Journavx in treating adults with moderate-to-severe acute pain. Unsurprisingly, investors reacted positively to ...